COMPANY NEWS


Glenmark Pharmaceuticals Ltd
BSE Code 532296 ISIN Demat INE935A01035 Book Value (₹) 651.23 NSE Symbol GLENMARK Div & Yield % 0.25 Market Cap ( Cr.) 28,770.49 P/E * 27.34 EPS * 37.29 Face Value (₹) 1
* Profit to Earning Ratio
* Earning Per Share
Glenmark Pharmaceuticals signs license agreement with Jiangsu Alphamab and 3DMed Back
(25 Jan 2024)

Glenmark Specialty S.A. (GSSA), a subsidiary of Glenmark Pharmaceuticals, today announced the signing of a license agreement with JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD (Jiangsu Alphamab) and 3D MEDICINES (BEIJING) CO., LTD. (3DMed), (together as the Licensors), for KN035 (Envafolimab) for India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America (the Territory).

Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3DMed, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory. Jiangsu Alphamab will be the exclusive supplier of the product. Jiangsu Alphamab (on behalf of the Licensors) will receive a low double digit Million US Dollar amount up to launch, additional triple digit Million US Dollar milestone payments based on sales performance across the length of the agreement, and a royalty fee of single-to-double-digits percentage according to the level of net sales.